Surrozen, Inc./DE — Form 8-K
Filed October 20, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Surrozen completed the second and final closing of its March 2025 private placement on October 20, 2026, raising approximately $95.1M in gross proceeds (before fees and expenses). The closing was triggered by FDA IND clearance for SZN-8141 on October 2, 2026. The company issued 5.7M common shares, 2.5M pre-funded warrant shares, and 4.1M Series E common warrant shares at $11.54 per share. Post-closing, Surrozen has 17.8M shares outstanding and expects cash runway into 2029 to fund the DUET Phase 1b/2a study of SZN-8141 and initial Phase 1b development of SZN-8143.
Why this rating
Financing equals 159% of $59.7M market cap, dramatically extending runway and de-risking near-term operations; however, massive dilution from ~5.7M shares + warrants (9.6M total dilution) substantially offsets benefit.
Price action (we called it positive)
before filing · preread $25.14 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.